SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic assays, products and services designed to provide
physicians with clinically actionable information to improve
patient outcomes, announces the results of a study analyzing
cerebrospinal fluid (CSF) samples in patients with primary lung or
breast cancer with either brain or leptomeningeal disease.
The findings indicate that Target Selector™ CSF assays are a
viable and sensitive platform for circulating tumor cell (CTC)
detection and molecular analysis compared to the current standard
of care, CSF cytology, which is typically used to establish or
confirm leptomeningeal disease when imaging findings are suspicious
or equivocal. CSF cytology has limited sensitivity and
provides no additional information needed for target therapy
choice.
The results were discussed yesterday in a poster presentation by
Santosh Kesari, MD, PhD, Chair and
Professor, Department of Translational Neurosciences, Director of
Neuro-oncology at the Pacific Neuroscience Institute and John Wayne
Cancer Institute, at the Society for Neuro-Oncology's SNO2020
Virtual Conference on November 19,
2020.
"Once a tumor has metastasized to the brain, CTCs and
circulating tumor DNA (ctDNA) can be found in the cerebrospinal
fluid," said Dr. Kesari. "This prospective study compared the
sensitivity of CTC detection and molecular analysis of
Biocept's Target Selector™ CSF assays to cytology (microscopic
examination of conventional CSF cytology slide preps). This
study highlights the potential of CSF-based diagnostics for
longitudinal monitoring cancers in the central nervous system."
"Our Target Selector™ testing is a minimally invasive,
cost-effective strategy to simultaneously confirm metastasis to the
brain, while also assessing cancer biomarkers in order to qualify a
patient for potential targeted therapy options," said
Michael Nall, President and CEO of
Biocept. "Identifying CTCs and actionable biomarkers with
Target Selector™ can help to confirm and monitor central nervous
system involvement when clinically suspected, without the risk of
complications associated with surgical biopsies, which are often
impossible in these cases.
"This the second major scientific conference in less than two
months to accept study results from Target Selector™ testing in
cerebrospinal fluid for presentation," added Mr. Nall. "We
view neuro-oncology as an area where our technology is uniquely
suited to answer questions posed by treating physicians, and we are
appreciative of the Society of Neuro-Oncology's recognition of our
Target Selector™ testing."
About the SNO2020 Virtual Conference
The Society for Neuro-Oncology exists to advance
multi-disciplinary brain tumor research, education, and
collaboration to drive discovery and improve patient care.
Over 2,600 neuro-oncology professionals are expected to
register for the SNO2020 Virtual Conference being held November 19-21, 2020. More information can
be found at soc-neuro-onc.org.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options.
Additionally, Biocept is offering nationwide COVID-19
polymerase chain reaction (PCR) testing to support public health
efforts during this unprecedented pandemic. For more
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding neuro-oncology being an area where Biocept's
technology is uniquely suited to answer questions posed by treating
physiciansthe ability of Biocept's platform to identify cancer
mutations and alterations to inform physicians about a patient's
disease and therapeutic options, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/study-shows-biocepts-assays-are-viable-and-sensitive-for-detecting-tumor-cells-and-biomarkers-in-the-cerebrospinal-fluid-of-patients-with-breast-and-lung-cancer-that-has-metastasized-to-the-central-nervous-system-301177929.html
SOURCE Biocept, Inc.